Chardan Capital initiated coverage on Tenaya Therapeutics with a new price target
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Chardan Capital initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $37.00